ShanX Medtech B.V. announces the successful closing of a total of EUR 24 million in financing to accelerate the development and commercialization of its ultra-rapid antimicrobial susceptibility testing (AST) platform. This includes an oversubscribed EUR 15 million seed round, comprising equity, grants, and the Innovatiekrediet, led by Borski Fund, NextGen Ventures, CbusineZ, Brabantse Ontwikkelings Maatschappij (BOM), Invest-NL, and a strategic angel fund. The financing is further complemented by the recently announced EUR 8.85 million EU procurement contract launched by DG HERA and HaDEA.

The obtained funding accelerates the final development, clinical validation, regulatory approval, and commercial launch of the novel diagnostic platform, which is already seeing heavy interest from healthcare and commercial partners.